DOXIMITY INC-CLASS A (DOCS) Stock Fundamental Analysis
NYSE:DOCS - New York Stock Exchange, Inc. - US26622P1075 - Common Stock - Currency: USD
DOCS gets a fundamental rating of 7 out of 10. The analysis compared the fundamentals against 36 industry peers in the Health Care Technology industry. Both the health and profitability get an excellent rating, making DOCS a very profitable company, without any liquidiy or solvency issues. DOCS is not overvalued while it is showing excellent growth. This is an interesting combination. These ratings would make DOCS suitable for growth and quality investing!
1. Profitability
1.1 Basic Checks
DOCS had positive earnings in the past year.
DOCS had a positive operating cash flow in the past year.
Each year in the past 5 years DOCS has been profitable.
Each year in the past 5 years DOCS had a positive operating cash flow.
1.2 Ratios
DOCS has a better Return On Assets (17.65%) than 100.00% of its industry peers.
DOCS's Return On Equity of 20.62% is amongst the best of the industry. DOCS outperforms 100.00% of its industry peers.
DOCS's Return On Invested Capital of 17.07% is amongst the best of the industry. DOCS outperforms 100.00% of its industry peers.
DOCS had an Average Return On Invested Capital over the past 3 years of 14.17%. This is significantly above the industry average of 6.38%.
The 3 year average ROIC (14.17%) for DOCS is below the current ROIC(17.07%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 17.65% | ||
| ROE | 20.62% | ||
| ROIC | 17.07% |
ROA(3y)13.75%
ROA(5y)12.65%
ROE(3y)16.22%
ROE(5y)15.68%
ROIC(3y)14.17%
ROIC(5y)16.48%
1.3 Margins
DOCS's Profit Margin of 39.13% is amongst the best of the industry. DOCS outperforms 100.00% of its industry peers.
In the last couple of years the Profit Margin of DOCS has grown nicely.
DOCS has a Operating Margin of 40.34%. This is amongst the best in the industry. DOCS outperforms 100.00% of its industry peers.
DOCS's Operating Margin has improved in the last couple of years.
Looking at the Gross Margin, with a value of 90.20%, DOCS belongs to the top of the industry, outperforming 97.22% of the companies in the same industry.
DOCS's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 40.34% | ||
| PM (TTM) | 39.13% | ||
| GM | 90.2% |
OM growth 3Y6.88%
OM growth 5Y16.16%
PM growth 3Y0.28%
PM growth 5Y33.35%
GM growth 3Y0.66%
GM growth 5Y0.68%
2. Health
2.1 Basic Checks
DOCS has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
Compared to 1 year ago, DOCS has more shares outstanding
Compared to 5 years ago, DOCS has more shares outstanding
There is no outstanding debt for DOCS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
DOCS has an Altman-Z score of 38.36. This indicates that DOCS is financially healthy and has little risk of bankruptcy at the moment.
DOCS has a better Altman-Z score (38.36) than 97.22% of its industry peers.
DOCS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 38.36 |
ROIC/WACC1.69
WACC10.11%
2.3 Liquidity
DOCS has a Current Ratio of 6.97. This indicates that DOCS is financially healthy and has no problem in meeting its short term obligations.
DOCS's Current ratio of 6.97 is amongst the best of the industry. DOCS outperforms 94.44% of its industry peers.
A Quick Ratio of 6.97 indicates that DOCS has no problem at all paying its short term obligations.
The Quick ratio of DOCS (6.97) is better than 94.44% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.97 | ||
| Quick Ratio | 6.97 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 48.42% over the past year.
Measured over the past years, DOCS shows a very strong growth in Earnings Per Share. The EPS has been growing by 79.21% on average per year.
Looking at the last year, DOCS shows a quite strong growth in Revenue. The Revenue has grown by 19.97% in the last year.
Measured over the past years, DOCS shows a very strong growth in Revenue. The Revenue has been growing by 37.42% on average per year.
EPS 1Y (TTM)48.42%
EPS 3Y20.79%
EPS 5Y79.21%
EPS Q2Q%52%
Revenue 1Y (TTM)19.97%
Revenue growth 3Y18.42%
Revenue growth 5Y37.42%
Sales Q2Q%17.14%
3.2 Future
The Earnings Per Share is expected to grow by 17.53% on average over the next years. This is quite good.
The Revenue is expected to grow by 10.57% on average over the next years. This is quite good.
EPS Next Y2.49%
EPS Next 2Y7.75%
EPS Next 3Y10.11%
EPS Next 5Y17.53%
Revenue Next Year10.63%
Revenue Next 2Y10.59%
Revenue Next 3Y10.52%
Revenue Next 5Y10.57%
3.3 Evolution
The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 42.06 indicates a quite expensive valuation of DOCS.
DOCS's Price/Earnings ratio is rather cheap when compared to the industry. DOCS is cheaper than 80.56% of the companies in the same industry.
When comparing the Price/Earnings ratio of DOCS to the average of the S&P500 Index (27.28), we can say DOCS is valued expensively.
A Price/Forward Earnings ratio of 41.04 indicates a quite expensive valuation of DOCS.
Based on the Price/Forward Earnings ratio, DOCS is valued a bit cheaper than the industry average as 61.11% of the companies are valued more expensively.
Compared to an average S&P500 Price/Forward Earnings ratio of 21.76, DOCS is valued quite expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 42.06 | ||
| Fwd PE | 41.04 |
4.2 Price Multiples
DOCS's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. DOCS is cheaper than 66.67% of the companies in the same industry.
69.44% of the companies in the same industry are more expensive than DOCS, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 41.76 | ||
| EV/EBITDA | 38.81 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates DOCS does not grow enough to justify the current Price/Earnings ratio.
DOCS has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)16.92
PEG (5Y)0.53
EPS Next 2Y7.75%
EPS Next 3Y10.11%
5. Dividend
5.1 Amount
DOCS does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
59.31
+0.93 (+1.59%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)
Earnings (Next)
Inst Owners93.81%
Inst Owner Change7.32%
Ins Owners2.25%
Ins Owner Change-2.03%
Market Cap11.14B
Analysts74.62
Price Target62.73 (5.77%)
Short Float %4.18%
Short Ratio2.16
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)33.65%
Min EPS beat(2)30.62%
Max EPS beat(2)36.67%
EPS beat(4)4
Avg EPS beat(4)26.68%
Min EPS beat(4)15.86%
Max EPS beat(4)36.67%
EPS beat(8)8
Avg EPS beat(8)24.85%
EPS beat(12)12
Avg EPS beat(12)22.9%
EPS beat(16)16
Avg EPS beat(16)34.8%
Revenue beat(2)2
Avg Revenue beat(2)4.77%
Min Revenue beat(2)1.38%
Max Revenue beat(2)8.16%
Revenue beat(4)4
Avg Revenue beat(4)4.65%
Min Revenue beat(4)1.38%
Max Revenue beat(4)8.16%
Revenue beat(8)6
Avg Revenue beat(8)2.85%
Revenue beat(12)8
Avg Revenue beat(12)1.88%
Revenue beat(16)12
Avg Revenue beat(16)3.35%
PT rev (1m)-14.86%
PT rev (3m)-18.38%
EPS NQ rev (1m)-1.75%
EPS NQ rev (3m)-2.11%
EPS NY rev (1m)8.19%
EPS NY rev (3m)-0.02%
Revenue NQ rev (1m)-0.16%
Revenue NQ rev (3m)-2.5%
Revenue NY rev (1m)-1.37%
Revenue NY rev (3m)-1.6%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 42.06 | ||
| Fwd PE | 41.04 | ||
| P/S | 19.53 | ||
| P/FCF | 41.76 | ||
| P/OCF | 40.77 | ||
| P/B | 10.29 | ||
| P/tB | 11.23 | ||
| EV/EBITDA | 38.81 |
EPS(TTM)1.41
EY2.38%
EPS(NY)1.45
Fwd EY2.44%
FCF(TTM)1.42
FCFY2.39%
OCF(TTM)1.45
OCFY2.45%
SpS3.04
BVpS5.76
TBVpS5.28
PEG (NY)16.92
PEG (5Y)0.53
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 17.65% | ||
| ROE | 20.62% | ||
| ROCE | 20.77% | ||
| ROIC | 17.07% | ||
| ROICexc | 98.29% | ||
| ROICexgc | 186.54% | ||
| OM | 40.34% | ||
| PM (TTM) | 39.13% | ||
| GM | 90.2% | ||
| FCFM | 46.76% |
ROA(3y)13.75%
ROA(5y)12.65%
ROE(3y)16.22%
ROE(5y)15.68%
ROIC(3y)14.17%
ROIC(5y)16.48%
ROICexc(3y)82.49%
ROICexc(5y)193.92%
ROICexgc(3y)186.25%
ROICexgc(5y)N/A
ROCE(3y)17.25%
ROCE(5y)20.05%
ROICexcg growth 3Y3.35%
ROICexcg growth 5YN/A
ROICexc growth 3Y-4.75%
ROICexc growth 5YN/A
OM growth 3Y6.88%
OM growth 5Y16.16%
PM growth 3Y0.28%
PM growth 5Y33.35%
GM growth 3Y0.66%
GM growth 5Y0.68%
F-Score9
Asset Turnover0.45
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 61.22% | ||
| Cap/Sales | 1.14% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 113.5% | ||
| Profit Quality | 119.52% | ||
| Current Ratio | 6.97 | ||
| Quick Ratio | 6.97 | ||
| Altman-Z | 38.36 |
F-Score9
WACC10.11%
ROIC/WACC1.69
Cap/Depr(3y)59.31%
Cap/Depr(5y)83.25%
Cap/Sales(3y)1.28%
Cap/Sales(5y)1.55%
Profit Quality(3y)131.35%
Profit Quality(5y)169.54%
High Growth Momentum
Growth
EPS 1Y (TTM)48.42%
EPS 3Y20.79%
EPS 5Y79.21%
EPS Q2Q%52%
EPS Next Y2.49%
EPS Next 2Y7.75%
EPS Next 3Y10.11%
EPS Next 5Y17.53%
Revenue 1Y (TTM)19.97%
Revenue growth 3Y18.42%
Revenue growth 5Y37.42%
Sales Q2Q%17.14%
Revenue Next Year10.63%
Revenue Next 2Y10.59%
Revenue Next 3Y10.52%
Revenue Next 5Y10.57%
EBIT growth 1Y33.93%
EBIT growth 3Y26.56%
EBIT growth 5Y59.63%
EBIT Next Year12.42%
EBIT Next 3Y11.62%
EBIT Next 5Y11.91%
FCF growth 1Y49.61%
FCF growth 3Y30.18%
FCF growth 5Y64.72%
OCF growth 1Y48.44%
OCF growth 3Y29.24%
OCF growth 5Y59.83%